Adial Pharmaceuticals, Inc.
ADIL
$6.44
-$0.21-3.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 369.57% | 3.20% | 4.64% | 5.36% | -9.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 210.31% | -11.72% | -2.85% | -20.23% | -17.72% |
| Operating Income | -210.31% | 11.72% | 2.85% | 20.23% | 17.72% |
| Income Before Tax | -2,555.21% | 9.26% | 3.60% | 18.16% | 20.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2,555.21% | 9.26% | 3.60% | 18.16% | 20.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,555.21% | 9.26% | 3.60% | 18.16% | 20.35% |
| EBIT | -210.31% | 11.72% | 2.85% | 20.23% | 17.72% |
| EBITDA | -210.32% | 11.73% | 2.85% | 20.23% | 17.72% |
| EPS Basic | -144.11% | 82.68% | 77.39% | 78.46% | 68.64% |
| Normalized Basic EPS | 101.17% | 83.77% | 77.39% | 78.46% | 68.64% |
| EPS Diluted | -144.11% | 82.68% | 77.39% | 78.46% | 68.64% |
| Normalized Diluted EPS | 101.17% | 83.77% | 77.39% | 78.46% | 68.64% |
| Average Basic Shares Outstanding | 987.71% | 423.74% | 326.34% | 279.99% | 153.97% |
| Average Diluted Shares Outstanding | 987.71% | 423.74% | 326.34% | 279.99% | 153.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |